Objectives
To evaluate treatment of acute bacterial meningitis with differing volumes of initial fluid administration (up to 72 hours after first presentation) and the effects on death and neurological sequelae.
Search methods
For this 2016 update we searched the following databases up to March 2016: the Cochrane Acute Respiratory Infections Group's Specialised Register, CENTRAL, MEDLINE, CINAHL, Global Health, and Web of Science.
Selection criteria
Randomised controlled trials (RCTs) of differing volumes of fluid given in the initial management of bacterial meningitis were eligible for inclusion.
Data collection and analysis
All four of the original review authors extracted data and assessed trials for quality in the first publication of this review (one author, ROW, has passed away since the original review; see Acknowledgements). The current authors combined data for meta-analysis using risk ratios (RRs) for dichotomous data or mean difference (MD) for continuous data. We used a fixed-effect statistical model. We assessed the overall quality of evidence using the GRADE approach.
Main results
We included three trials with a total of 420 children; there were no trials in adult populations. The largest of the three trials was conducted in settings with high mortality rates and was judged to have low risk of bias for all domains, except performance bias which was high risk. The other two smaller trials were not of high quality.The meta-analysis found no significant difference between the maintenance-fluid and restricted-fluid groups in number of deaths (RR 0.82, 95% confidence interval (CI) 0.53 to 1.27; 407 participants; low quality of evidence) or acute severe neurological sequelae (RR 0.67, 95% CI 0.41 to 1.08; 407 participants; low quality of evidence). However, when neurological sequelae were defined further, there was a statistically significant difference in favour of the maintenance-fluid group for spasticity (RR 0.50, 95% CI 0.27 to 0.93; 357 participants) ; and seizures at both 72 hours (RR 0.59, 95% CI 0.42 to 0.83; 357 participants) and 14 days (RR 0.19, 95% CI 0.04 to 0.88; 357 participants). There was very low quality of evidence favouring maintenance fluid over restrictive fluid for chronic severe neurological sequelae at three months followup (RR 0.42, 95% CI 0.20 to 0.89; 351 participants).
Authors' conclusions
The quality of evidence regarding fluid therapy in children with acute bacterial meningitis is low to very low and more RCTs need to be conducted. There is insufficient evidence to guide practice as to whether maintenance fluids should be chosen over restricted fluids in the treatment of acute bacterial meningitis.
P L A I N L A N G U A G E S U M M A R Y

Fluids for people with acute bacterial meningitis
Review question
Why is the effect of differing volumes of initial fluid administration on death and various neurological sequelae in people with acute bacterial meningitis important?
Background
Bacterial meningitis is an infection of the fluid in the spinal cord and surrounding the brain. Antibiotics are prescribed as treatment. Supportive care includes other drugs and the regulation of fluid intake. There has been disagreement about whether fluids should be restricted or unrestricted as there are potential risks from giving too much fluid (brain swelling) as well as too little fluid (shock).
Study characteristics
The evidence is current to March 2016. We did not find any trials in adult populations and included three trials involving 420 children. All trials were set in countries where death rates for meningitis are high. In one study no funding source was mentioned. The remaining two studies were funded jointly by pharmaceutical concerns with government agencies and a charitable agency.
Key results
No studies reported important healthcare outcomes such as duration of hospital stay, raised intracranial pressure, or status epilepticus. An adverse effect in children with restricted fluid intake was that they were less likely to have low levels of sodium in their blood and therefore they would experience greater reductions in body fluids. An adverse effect of unrestricted fluid administration was reported in one study as short-term swelling of the face and low blood sodium levels one to two days after fluids were started, although the largest study found no difference in blood sodium levels.
The review found limited evidence from these trials in support of not restricting fluids in settings with high mortality rates. There is no evidence to guide clinicians about fluid therapy in adult patients with acute bacterial meningitis. There is a need for more research on these aspects in the future.
Quality of the evidence
Analysis of available trials found low quality evidence that there is no significant difference between maintenance versus restrictive fluid regimens for the outcome of death and acute severe neurological complications. There was also some evidence favouring maintenance fluid therapy over restricted fluids for chronic severe neurological events at three months follow-up, but the quality was very low. GRADE Working Group grades of evidence High quality: Further research is very unlikely to change our conf idence in the estim ate of ef f ect. M oderate quality: Further research is likely to have an im portant im pact on our conf idence in the estim ate of ef f ect and m ay change the estim ate. Low quality: Further research is very likely to have an im portant im pact on our conf idence in the estim ate of ef f ect and is likely to change the estim ate. Very low quality: We are very uncertain about the estim ate.
S U M M A R Y O F F I N D I N G S F O R T H E M A I N C O M P A R I S O N
1 Total num ber of events is sm all and 95% CI around pooled estim ate includes both appreciable benef it and harm s.
2 Duke 2002 and Singhi 1995 both were deem ed to have high risk of bias f or blinding. However, this would not have any ef f ect on outcom e assessm ent f or the outcom e of death and acute severe neurological sequelae. Singhi 1995 was deem ed at high risk f or reporting bias but we did not downgrade f or risk of bias because sensitivity analyses did not change ef f ect estim ates signif icantly.
3 Duke 2002 -high risk of bias due to im proper blinding would af f ect outcom e assessm ent f or chronic severe neurological sequelae. 4 Total num ber of events is not large enough f or precision.
B A C K G R O U N D Description of the condition
Acute bacterial meningitis remains a disease with high mortality and morbidity rates. The outcome in individuals with bacterial meningitis is correlated with many factors, including the age of the person, time and clinical stability before effective antibiotic treatment is begun, type of micro-organism, number of bacteria or quantity of active bacterial products in the cerebrospinal fluid (CSF) at the time of diagnosis, intensity of the host's inflammatory response, and time elapsed to sterilise CSF cultures (Feldman 1977; Mustafa 1990; Saez-Llorens 1990; Waage 1987) .
Description of the intervention
The highest rates of mortality and morbidity occur in the neonatal period and in the elderly. Nearly one in four adults with the illness will die, and many survivors sustain neurological deficits (Bohr 1983; Pfister 1993) . Bacterial meningitis causes more than 100,000 deaths worldwide each year in infants and young children (Duke 1998). A 1993 meta-analysis examined the overall and organism-specific frequencies of death and persistent neurological sequelae in children two months to 19 years of age (Baraff 1993) . A total of 4920 children with acute bacterial meningitis were included in 45 reports that met the inclusion criteria. Children described in the 19 reports of prospectively-enrolled cohorts from high-income countries had lower mortality than the children included in trials from low-income countries (4.8% versus 8.1%) and were more likely to have no sequelae (82.5% versus 73.9%). A further study that examined the long-term consequences of having meningitis during the first year of life found that 1.8% of children died within five years (Bedford 2001) . Not only did almost a fifth of children with meningitis have a subsequent permanent, severe, or moderately severe disability, but subtle deficits were also more prevalent.
How the intervention might work
The chances for survival are improved with prompt and adequate antimicrobial and supportive treatment, especially in infants and children, for whom case fatality rates have been reduced to less than 10% for bacterial meningitis and less than 5% for meningococcal meningitis (Saez-Llorens 2003) . Two Cochrane Reviews examine the effectiveness and safety of steroids and different antibiotic regimens, respectively, which are used in the treatment of acute bacterial meningitis (Brouwer 2015; Prasad 2011) . Careful management of fluid and electrolyte balance is also important in the treatment of meningitis. Over-or under-hydration are associated with adverse outcomes. Fluid restriction in the initial management of meningitis in children has been widely advocated (Conner 1980; Feigin 1992) . However, this has also been challenged (Conner 1980; Powell 1990; Singhi 1995) . The practice of fluid restriction is based on reports of hyponatraemia (lower than normal concentration of sodium in the extracellular fluid/blood) that is attributed to increased concentrations of circulating antidiuretic hormone (ADH; a hormone that prevents excretion of water from the body). Over 50% of children have hyponatraemia at the time of admission (Kaplan 1983) . There are associations between the degree of hyponatraemia and the presence of seizures and severity of acute disease, and adverse neurodevelopmental outcomes (Feigin 1977) . These findings have subsequently been linked with a high incidence of cerebral oedema (swelling of the brain) in those who die from acute bacterial meningitis (Conner 1980; Dodge 1965; Williams 1964) , and it has been suggested that inappropriately increased concentrations of ADH lead to water retention, which in turn exacerbates cerebral swelling. Some researchers have concluded that fluid restriction will avoid exacerbating cerebral oedema and may improve neurological outcome (Brown 1994). However, clinical dehydration has also been found in children with acute bacterial meningitis without any accompanying significant risk of mortality (Duke 1998). It has also been found that in children who received maintenance fluid plus replacement of volume deficits, the high ADH concentrations normalised over 24 hours; in those who were restricted to two-thirds maintenance fluids, ADH concentrations remained high (Powell 1990 ). The conclusion from this was that ADH concentrations are increased in children with meningitis because of hypovolaemia (a decrease in the volume of circulating blood) and only become normal when sufficient sodium and fluid are given.
Why it is important to do this review
Although it is widely accepted that hyponatraemia is a marker of severe disease in childhood bacterial meningitis, there are different opinions regarding the cause of hyponatraemia at the time of presentation. If dehydration, rather than inappropriately increased antidiuresis, is the major factor in the pathogenesis of hyponatraemia in meningitis, then the rationale for fluid restriction is open to question.
O B J E C T I V E S
Criteria for considering studies for this review
Types of studies
Randomised controlled trials (RCTs) examining the effectiveness of different volumes of initial fluid administration in the treatment of acute bacterial meningitis were eligible for inclusion. We planned to consider trials of fluids administered to treat shock at presentation but we found no such trials.
Types of participants
All age groups with a diagnosis of acute bacterial meningitis, made either by clinical diagnosis or culture of cerebrospinal fluid (CSF) obtained at lumbar puncture, were eligible for inclusion. 
Types of interventions
Searching other resources
We searched references from included trials and contacted trial authors where necessary. In addition, we contacted experts in the field for unpublished works. We searched the following trial registers.
• ClinicalTrials.gov (clinicaltrials.gov; searched March 2016);
• World Health Organization International Clinical Trials Registry Platform (who.int/ictrp/en; searched 6 November 2013).
In much earlier versions the National Health and Medical Research Council (NHMRC) Clinical Trials Register (www.nhmrc.gov.au) and meta-register of controlled trials (www.isrctn.com ) was searched. We attempted to contact authors of all identified trials, whether open or unpublished. We sought publications in the literature that described, or may have described, the use of fluid therapy for the treatment of acute bacterial meningitis. We applied no language or publication status restrictions. We searched the citation lists of relevant publications, review articles, and abstracts of scientific meetings, and included both published and unpublished studies.
Data collection and analysis
Selection of studies
For this 2016 update, two review authors (SB, IM) independently screened all the search results for consideration of inclusion as per eligibility criteria based on title, abstract, and key words initially, and then after accessing full-texts. Any disagreements were to be resolved by consensus, with the Review Group Editor acting as an arbiter. For previous versions of this review, two review authors (HB, IM) undertook study selection after running the search strategies outlined above. Both review authors had independently assessed whether the studies met the inclusion criteria; any discrepancies then were to be resolved by a third author (ROW, see Acknowledgements) but this proved unnecessary. We sought further information from the trial authors where papers contained insufficient information to make a decision about eligibility. We had to do this for two studies which we excluded based on these communications (Characteristics of excluded studies).
Data extraction and management
We collected information regarding location of the study, methods of the study (as per quality assessment checklist), participant characteristics (age range, eligibility criteria), types of interventions and outcomes for each included trial. Where possible, we sought missing data from the trial authors. Four review authors had previously (IM, HB, MS , ROW) independently performed data extraction. Any discrepancies were to be resolved by discussion but this proved unnecessary.
Assessment of risk of bias in included studies
We assessed the risk of bias in the included studies using the criteria described in the Cochrane Handbook for Systematic Reviews of Interventions (Higgins 2011). Two review authors independently extracted information about selection bias (random sequence generation and allocation concealment), detection bias (blinding of outcome assessment), attrition bias (incomplete outcome data), reporting bias (selective reporting), sample size, and exclusions after randomisation, and any other sources of bias .
Measures of treatment effect
We analysed each dichotomous outcome for effect in terms of a risk ratio (RR) with a 95% confidence interval (CI) and combined the outcomes for meta-analysis using Review Manager 5 software (RevMan 2014). Where data were sufficient, we calculated a summary statistic for each outcome using a fixed-effect model. We analysed continuous outcomes as mean differences (MDs) between groups and 95% CIs. Where data were sufficient, we used a fixed-effect approach in the meta-analysis. There were two kinds of effect estimates in our study. One, where only a single study contributed to the outcome, in which case a fixed-effect model was appropriate, and two, those pooled estimates where there was more than one study (two studies) and little evidence of heterogeneity was detected. Therefore, a fixed-effect model was used.
Unit of analysis issues
We did not include any studies with non-standard designs. The comparisons under consideration would not lend themselves to cluster-randomised or other similar designs.
Dealing with missing data
Where there were missing participants due to dropout, we searched for the use of an intention-to-treat (ITT) analysis by the trial authors and reported this in the review. Where there were missing statistics (such as, standard deviations or correlation coefficients) that made analysis impossible, we approached the trial authors. Where there remained missing data, we report this in the review.
Assessment of heterogeneity
We determined statistical heterogeneity by a combination of visual inspection of graphs of RRs as well as using the I² statistic (Higgins 2003) , and the Chi² test.
Assessment of reporting biases
We had intended to investigate for publication bias and other reporting biases initially by the use of funnel plots. However, as there were only three included studies, we were unable to do so.
Data synthesis
We entered and analysed all data using Review Manager 5 software (RevMan 2014). We discuss methods of analyses for subgroup analysis, investigation of heterogeneity, and sensitivity analyses in the relevant sections.
GRADE and 'Summary of findings' table
For the 2014 update, two authors (SB, IM) used the GRADE approach to interpret the findings (Schunemann 2011). We used the GRADE profiler software (GRADEpro GDT 2014), and imported data from RevMan 2014 to create Summary of findings for the main comparison containing the following outcomes: death, and acute and chronic severe neurological sequelae. We used the five GRADE considerations (study limitations, consistency of effect, imprecision, indirectness, and publication bias) to assess the quality of a body of evidence as it relates to the studies which contribute data to the meta-analyses for the prespecified outcomes (Atkins 2004). We used methods and recommendations described in Section 8.5 and Chapter 12 of the Cochrane Handbook for Systematic Reviews of Interventions (Higgins 2011). Summary of findings for the main comparison provides information about the overall quality of evidence from trials, the magnitude of effect of the interventions, as well as the sum of the available data for the primary outcomes. We justified all decisions to down-or upgrade the quality of studies using footnotes, and we made comments to aid the reader's understanding of the review where necessary.
Subgroup analysis and investigation of heterogeneity
We had planned that if there were a sufficient number of trials of adequate size, with the required information recorded in the trial publication, we would conduct subgroup analyses by:
• age;
• volume of fluid administered;
• organism causing the meningitis;
• hypoperfusion status at enrolment; and • clinical diagnosis versus laboratory-confirmed diagnosis.
We assessed clinical heterogeneity by establishing the overall mortality rates and duration of symptoms, where possible. We used this to distinguish between participants studied in different health settings. We did not deem meta-analysis appropriate where it was evident that studies were undertaken in different health contexts.
Sensitivity analysis
We had planned to perform an a priori sensitivity analysis on results to look at the possible contribution of differences in methodological quality, but we were unable to do this due to the paucity of trials.
R E S U L T S Description of studies
Results of the search
For this 2016 update we identified 824 records (CENTRAL = 128, CINAHL = 29, Global Health = 298, MEDLINE = 221, Web of Science = 133, ClinicalTrials.gov = 14, reference searching = 1). After removing duplicates (n = 139), we screened 685 records. We recovered full-texts for three of them (Pelkonen 2011; Roine 2014; van Paridon 2015) , but we did not find any to be eligible for inclusion. Reasons for exclusion are documented in the Characteristics of excluded studies table.
For the 2014 update, with duplicates removed (including duplicates of the records sent in 2010) there were 496 search results. We removed animal studies (n = 49) and screened 447 search results (Maconochie 2014) . We excluded 445 search results on the basis of title or abstract and two on the basis of full-text inspection. We did not find any studies in the grey literature. Reasons for exclusion are given in the Characteristics of excluded studies table.
In the 2011 update, six abstracts identified in the search initially appeared to fit the inclusion criteria for the review (Maconochie 2011) . After obtaining the full papers, we excluded three of these, leaving three trials eligible for inclusion (420 children). In the 2008 update, we retrieved 105 records from the search of the electronic databases but did not find any new included trials for inclusion (Maconochie 2008) .
Included studies 1. Trial design characteristics
Volume and constitution of fluid
The Duke 2002 trial compared milk-based fluids delivered at 60% of that required for maintenance fluids with 100% of normal maintenance fluids. Maintenance fluids were defined as "100 ml/ kg/day for the first 10 kg of body weight, 50 ml/kg for the second 10 kg, and 20 ml/kg for over 20 kg". The milk-based fluids comprised expressed breast milk or other milk feed given via a nasogastric tube for at least 48 hours, or longer with reduced conscious state, convulsions, impaired upper airway reflexes, or persistent respiratory distress. Normal maintenance fluids (defined as above) of a solution containing 0.45% sodium chloride and 5% dextrose plus 10 mmol/L of potassium chloride per litre were delivered intravenously for at least the first 48 hours. The Powell 1990 trial compared two-thirds of required maintenance fluids (similarly defined as "100 ml/kg for the first 10 kg of body weight, plus 50 ml/kg for the next 10 kg (10 kg to 20 kg), plus 20 ml/kg for each kilogram in excess of 20 kg") with full maintenance fluids, plus replacement fluids for any estimated deficit over 24 hours. Rehydration was begun by administering 10 ml/kg or 15 ml/kg by rapid intravenous infusion. Fluids were given intravenously with the composition determined by the attending consultant. The Singhi 1995 trial compared restricted fluids at 65% of the calculated maintenance fluid requirement with maintenance fluid requirements (110 ml/kg for first 10 kg, 50 ml/kg for next 10 kg and 25 ml/kg for subsequent weight), both given intravenously. The restricted fluids comprised one-fifth normal saline in 5% dextrose for 24 hours, followed by "a gradual liberalisation at a rate of 10 ml/kg over eight hours, if, after 24 hours of hospital stay, the serum sodium and plasma osmolality had returned to normal and there were no clinical signs of dehydration".
Duration of fluid therapy
The Duke 2002 study administered fluids for 48 hours; the Powell 1990 study administered fluids for 24 hours; and the Singhi 1995 study administered fluids for 24 hours, with a gradual increase thereafter until children in both arms received the full normal maintenance requirement after 48 hours.
Baseline characteristics of participants
Age
All studies included only children. Duke 2002 included children between one month and 12 years of age, Powell 1990 included children between three months and 16 years, and Singhi 1995 included children between two months and seven years of age.
Health status
The children in the study carried out in Papua New Guinea were from a population in which 25% were undernourished at the time of their presentation (Duke 2002). In regard to the meningitis symptoms, the mean duration of symptoms was six days, with twothirds of children having convulsions, before presentation; 20% of the children were hypoglycaemic. The Powell 1990 study gave no specific details, but said that they only enrolled "previously healthy children". Malnourished children were excluded from the Singhi 1995 study, and children had a duration of symptoms ranging from one to 10 days on presentation.
Diagnostic techniques used to establish a diagnosis of bacterial meningitis
The Duke 2002 study made a diagnosis according to clinical signs of meningitis and a cloudy or turbid cerebrospinal fluid (CSF) with a moderate or large number of leucocytes and amount of protein, determined by dipstick testing (Multistix 10 SG). The Powell 1990 study diagnosed meningitis on the basis of clinical examination, CSF cytology, and chemical studies. The Singhi 1995 study made a diagnosis on a suggestive history, physical examination, CSF findings of hypoglycorrhachia, increased protein concentration, and polymorphonuclear leucocytosis.
Studied outcomes
Death
Two studies reported death as an outcome (Duke 2002; Singhi 1995) . Personal communication with the lead author of the Powell 1990 study reported no fatalities.
Short-term (within the first four weeks of illness) and longterm (persisting after the first four weeks of illness) neurological sequelae
Two studies reported acute neurological sequelae (Duke 2002; Singhi 1995) . One of these studies also reported individual neurological components at 14 days (spasticity, hemiparesis/hemiplegia, visual impairment, and no response to sound) and neurological sequelae at three months (Duke 2002).
Seizures
Duke 2002 reported the incidence of seizures at both 72 hours and 14 days. In the 2014 update of this review, 'seizures' was not treated as a separate secondary outcome since this outcome is already captured within the primary outcome 'acute (short-term) neurological sequelae'.
Oedema (including cerebral)
One study reported facial oedema, pulmonary oedema, and hydrocephalus (Duke 2002).
Total body water
One study reported total body water as an outcome (Singhi 1995).
Extracellular water
One study reported extracellular water as an outcome (Singhi 1995).
Serum and urinary sodium
Two studies reported comparisons of mean serum-sodium concentrations (Powell 1990; Singhi 1995) . Duke 2002 reported the proportion of children with serum-sodium concentrations below 130 mmol/litre at 72 hours. One study reported urinary sodium as an outcome (Singhi 1995).
Plasma and urinary osmolality
One study reported plasma and urinary osmolality as an outcome (Singhi 1995).
Duration of hospital stay
No study reported duration of hospital stay as an outcome.
Raised intracranial pressure
No study reported on raised intracranial pressure.
Status epilepticus
No study reported on incidence of status epilepticus.
Excluded studies
We excluded three studies as they were not RCTs (Brown 1994; Duke 1998; Floret 1999) , one study because the interventions and comparators were not relevant (Berkley 2004), and another study because insufficient data on culture-positive bacterial meningitis were available (Maitland 2013).
Risk of bias in included studies
A graphical representation of the risk of bias for the included studies is shown in Figure 1 . A summary of methodological quality of the included trials is given in Figure 2 . 
Allocation
Two studies used opaque, sealed, sequentially-numbered envelopes (Duke 2002; Powell 1990) . The remaining study used a random numbers table (Singhi 1995) and judged to have low risk. Two trials displayed adequate allocation concealment (Duke 2002; Powell 1990 ). The quality of allocation concealment in the third study was unclear (Singhi 1995).
Blinding Performance bias
Blinding of participants and personnel was high risk for all trials
Detection bias
This was judged to be low risk for all the three trials for the outcomes of death and acute severe neurological sequelae as clinically they are quite objective and obvious even though no blinding was done.Since no blinding was done for outcome assessment it would be high risk for the outcome of chronic sever neurological sequale where the clinical manifestation would not be so obvious.
Attrition bias
The attrition bias was found to be low risk for two trials (Duke 2002; Singhi 1995) and high risk for one (Powell 1990 ).
Reporting bias
Reporting bias was found to be high risk in two studies (Powell 1990; Singhi 1995) and low risk in one study (Duke 2002) .
Power calculations
Two studies documented power calculations (Duke 2002; Singhi 1995) . Duke 2002 calculated a required participation of 354 to detect a one-third reduction in adverse outcomes. The study randomised 357 children and analysed results for 346 children immediately at completion of treatment. Singhi 1995 calculated that 31 children in each group were needed to detect a 25% change in intact survival rate from 50%, with a significance of 0.05. This study was terminated early, but enrolled 25 in each group.
Number of centres
Duke 2002 had three participating centres. The remaining two were single-centre studies (Powell 1990; Singhi 1995) .
Intention-to-treat (ITT) analysis
No study reported an ITT analysis.
Incomplete outcome data
The largest study had relatively small numbers of dropouts (11 of 357 enrolled children) by the end of treatment, when most of the outcomes were measured (Duke 2002). By three months from diagnosis there were over 10% dropouts. The Powell 1990 study had five exclusions from 24 children enrolled, and this would have introduced the possibility of significant bias. Singhi 1995 had no dropouts.
Selective reporting
There was no evidence of selective reporting of data in Duke 2002; both short-term and longer-term morbidities were reported. Powell 1990 only reported short-term sodium levels. Singhi 1995 only reported total numbers with short-term neurological impairment and did not attempt to break these down by type of impairment.
Other potential sources of bias
The main concern was the marked discrepancy in size between the largest study and the two other very small RCTs. The Singhi 1995 trial was stopped prematurely owing to observance of "a trend toward poor outcome in the restricted-fluid group", and this is also a potential source of bias. 
Effects of interventions
All participants, regardless of serum sodium at enrolment
The meta-analysis of the three studies (420 children) for deaths (Duke 2002; Powell 1990; Singhi 1995) , where one study reported no fatality amongst their participants (Powell 1990), found no significant difference between deaths in the maintenance-fluid and restricted-fluid groups; risk ratio (RR) 0.82, 95% confidence interval (CI) 0.53 to 1.27; low quality evidence (Summary of findings for the main comparison; Analysis 1.1.1).
Participants with or without hyponatraemia
The Singhi 1995 study that subdivided maintenance-fluid and restricted-fluid groups into children with or without hyponatraemia at presentation found no significant difference in death rates in either those presenting with hyponatraemia (26 children) or those without hyponatraemia (24 children). With hyponatraemia, the RR for children given the two different fluid intakes was RR 0.15, 95% CI 0.01 to 2.50 (Analysis 1.1.2); without hyponatraemia, the RR was 0.79, 95% CI 0.16 to 3.90 (Analysis 1.1.3).
Short-term (within the first four weeks of illness) and long-term (persisting after the first four weeks of illness) neurological sequelae
Short-term neurological sequelae
The meta-analysis of acute severe neurological sequelae (2 studies, 407 children) found no significant difference between the maintenance-fluids and restricted-fluids groups (RR 0.67, 95% CI 0.41 to 1.08; low quality evidence) (Summary of findings for the main comparison; Analysis 1.2.1). Data on mild to moderate sequelae at 14 days (1 study, 357 children) also showed no significant difference between maintenancefluid and restricted-fluid groups (RR 1.24, 95% CI 0.58 to 2.65) (Analysis 1.3.1). However, when neurological sequelae were categorised further, the available data produced the following results.
• Hemiparesis/hemiplegia (1 study, 357 children): no significant difference between groups (RR 0.97, 95% CI 0.52 to 1.81) (Analysis 1.4.1).
• Spasticity (1 study, 357 children): there was a statistically significant difference in favour of the maintenance-fluid group (RR 0.50, 95% CI 0.27 to 0.93) (Analysis 1.5.1).
• Seizures (1 study, 357 children): there was a statistically significant difference in seizure activity at both 72 hours (RR 0.59, 95% CI 0.42 to 0.83) and 14 days (RR 0.19, 95% CI 0.04 to 0.88) in favour of the maintenance-fluid group (Analysis 1.6).
• Visual impairment and response to sound (1 study, 357 children): there was no statistically significant difference in either group. On visual impairment the RR was 0.77, 95% CI 0.44 to 1.35 (Analysis 1.7) and on response to sound, RR 0.60, 95% CI 0.25 to 1.41 (Analysis 1.8).
Participants with or without hyponatraemia
Analyses of data from participants with and without hyponatraemia at presentation showed no significant difference in acute neurological sequelae for either subgroup. Without hyponatraemia, the RR for children given maintenance fluids or restricted fluids was RR 0.59, 95% CI 0.13 to 2.64 (Analysis 1.2.3); with hyponatraemia, RR 0.91, 95% CI 0.34 to 2.47 (Analysis 1.2.4).
Long-term neurological sequelae
The data relating to chronic severe neurological sequelae (1 study, 351 children) showed a statistically significant difference at threemonth follow-up in favour of those in the maintenance-fluid groups: RR 0.42, 95% CI 0.20 to 0.89; very low quality evidence (Summary of findings for the main comparison; Analysis 1.2.2).
Secondary outcomes 1. Oedema (including cerebral)
The data on facial oedema (1 study, 357 children) showed a statistically significant difference in favour of the restricted-fluids group: RR 5.47, 95% CI 2.65 to 11.27. There was no statistically significant difference in either pulmonary oedema (RR 8.75, 95% CI 0.47 to 161.38) or hydrocephalus (RR 0.28, 95% CI 0.06 to 1.32) (Analysis 1.9).
Total body water
The data on change in total body water at 48 hours after admission (1 study; 24 children without hyponatraemia, 26 children with hyponatraemia) showed a statistically significantly greater reduction in the restricted-fluids group in both non-hyponatraemic and hyponatraemic children: mean difference (MD) (meq/litre) 24.50, 95% CI 9.91 to 39.09; and MD (meq/litre) 36.00, 95% CI 19.83 to 52.17, respectively (Analysis 1.10).
Extracellular water
The data on reduction in extracellular water at 48 hours after admission (1 study; 24 children without hyponatraemia, 26 children with hyponatraemia) showed a greater reduction in the restricted-fluid groups: non-significant for non-hyponatraemic children: MD (meq/litre) 22.90, 95% CI -1.11 to 46.91; and a statistically significant change in hyponatraemic children: MD (meq/ litre) 35.00, 95% CI 16.86 to 53.14 (Analysis 1.11).
Serum and urinary sodium
Duke 2002 reported the proportion of children with serum sodium concentrations below 130 mmol/litre at 72 hours and found no statistically significant difference between the restrictedfluid and maintenance-fluid groups: RR 0.72, 95% CI 0.34 to 1.55 (Analysis not shown).
We did not attempt a meta-analysis of the two studies comparing mean sodium concentrations, as Powell 1990 measured serum sodium at 24 hours and Singhi 1995, at 48 hours. The Powell 1990 study (13 children with bacterial meningitis) reported all children together and found no statistically significant difference in mean serum sodium at 24 hours: MD (meq/litre) 3.00, 95% CI -0.94 to 6.94. The Singhi 1995 study (1 study; 24 children without hyponatraemia, 26 children with hyponatraemia) subgrouped children by hyponatraemia status at study entry. The study found a statistically significant difference in favour of the restricted-fluid group in children with hyponatraemia (MD (meq/litre) -4.20, 95% CI -6.20 to -2.2). In the original paper, the statistical difference in favour of restricted fluids in children without hyponatraemia (MD (meq/litre) -3.50, 95% CI -7.58 to 0.58, P = 0.09) was reported as statistically significant, but this is not the case, as evident from examination of the effect estimate and the 95% CI. This study also found a significant difference in the change in serum sodium from baseline, in favour of the restricted-fluid group, in children both with and without hyponatraemia. Without hyponatraemia, the MD (meq/litre) was -5.8, 95% CI -11.59 to -0.01; with hyponatraemia, MD (meq/litre) -4.40, 95% CI -6.97 to -1.83 (Analysis 1.12). The one study (24 children without hyponatraemia at admission, 26 children with hyponatraemia) that reported urinary sodium found no significant difference at 48 hours in mean urinary sodium in children without hyponatraemia (MD (meq/litre) -14.0, 95% CI -31.60 to 3.6) but a statistically significant difference in children with hyponatraemia at admission (MD (meq/litre) -21.00, 95% CI -34.14 to -7.86). There was no significant change from baseline at 48 hours either in children without hyponatraemia (MD (meq/litre) 1.00, 95% CI -12.22 to 14.22) or with hyponatraemia (MD (meq/litre) 0.0, 95% CI -8.94 to 8.94) (Analysis 1.13).
Plasma and urinary osmolality
There was a statistically significant difference in the change in plasma osmolality after 48 hours, with a greater increase in the restricted-fluid group, in both the children presenting without hyponatraemia (1 study, 24 children): MD (meq/litre) -5.00, 95% CI -9.82 to -0.18; and children presenting with hyponatraemia (1 study, 26 children): MD (meq/litre) -6.00, 95% CI -11.36 to -0.64 (Analysis 1.14).
Duration of hospital stay
No study reported on duration of hospital stay.
Raised intracranial pressure
Status Epilepticus
D I S C U S S I O N
Summary of main results
The small number of studies identified by this review did not show any statistically significant difference in mortality or acute severe neurological sequelae from restricting fluids. Two studies reported high mortality rates overall, well above 10% (Duke 2002; Singhi 1995; 407 children) . The third study included very small numbers (19 children analysed), and reported no deaths (Powell 1990) . Meta-analysis of the two studies reporting neurological sequelae demonstrated statistically significant reductions in the rates of early spasticity and seizures, and later overall neurological sequelae, in children receiving maintenance fluids. There were no statistically significant differences in overall short-term neurological sequelae or in risk of hemiparesis, visual, or hearing impairment. Two of the studies involved very small numbers of children from single centres (Powell 1990; Singhi 1995) . The mortality and morbidity results, therefore, are dominated by the Duke 2002 study. The long delays before presentation and a high rate of malnutrition in the children in this study may have been associated with a high rate of dehydration at presentation. The finding of a higher rate of neurological sequelae in the restricted-fluid group in this study could result from inadequate initial treatment of dehydration. This might not be relevant in settings where patients present earlier.
Overall completeness and applicability of evidence
The three included studies were insufficient to evaluate the review objective of evaluating different volumes of initial fluid administrations on treatment outcomes of acute bacterial meningitis. We did not find any trial answering the review question for adult patients. All the trials were conducted in in-hospital settings and no trials were carried out in primary care or out-of-hospital settings, where initial fluid therapy is often instituted, and the patients referred to a tertiary care set-up for specialised care. Trials done in out-ofhospital and primary healthcare settings might be more relevant to low-and middle-income nations, where healthcare delivery is not well monitored, and generally unstructured (Maher 2011). The largest of the three studies included multiple outcomes relevant to the review question (Duke 2002). Its shortcoming was that it could only address the question in settings with high mortality and morbidity rates and long delays before presentation.
The other two included studies were too small to allow any conclusions to be drawn. None of the studies included adults. The results of short-term fluid and electrolyte balance do not in themselves provide adequate evidence on which to change practice. The reporting of sodium levels was inconsistent so that it was not possible to undertake a meta-analysis. The quality of evidence for the primary and secondary outcomes was low to very low and thus insufficient to guide clinical practice.
Quality of the evidence
We assessed the overall quality of the evidence using the GRADE approach (Schunemann 2011), as shown in Summary of findings for the main comparison. The overall quality of the evidence for maintenance-fluid versus restricted-fluid regimens for children with acute bacterial meningitis was low for the outcomes of death, and acute severe neurological sequelae, and very low for chronic severe neurological sequelae. In this 2016 update we revised the GRADE table to reflect current Cochrane standards, and improve clarity and consistency of reporting results.
Potential biases in the review process
We searched a number of electronic databases using a number of search terms. We expect that our search strategy has been successful in identifying all relevant studies. Standard Cochrane methodologies have been used to minimise any bias in the review process.
Agreements and disagreements with other studies or reviews
There are no systematic reviews which have explored this research question.
A U T H O R S ' C O N C L U S I O N S Implications for practice
There is a lack of high quality evidence to guide the use of fluid therapy for acute bacterial meningitis. There are no trials in adult or elderly populations; all trials were in children. The meta-analysis found no significant difference between the maintenance-fluid and restricted-fluid groups in number of deaths (low quality of evidence), or acute severe neurological sequelae (low quality of evidence). Some evidence was found favouring maintenance fluid over restrictive regimens for the outcome of chronic severe neurological sequelae events at three months follow-up, although the quality of evidence is very low and hence not enough to guide practice. Most of the evidence was from high mortality setting.
Implications for research
Future randomised clinical trials should evaluate maintenance fluid versus restricted fluid for acute bacterial meningitis. Trials in adult populations, particularly elderly populations, are needed and in countries with high and low mortality rates for acute bacterial meningitis. Large, high quality trials are also needed to assess the effectiveness of either restricting or administering maintenance fluids in populations where people present early and where mortality rates are low. Trials also need to focus on important outcomes such as duration of hospital stay and raised intracranial pressure.
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